Biomarkers for Prediction of Skeletal Disease Progression in Mucopolysaccharidosis Type I

Overview

Journal JIMD Rep

Publisher Wiley

Date 2021 Mar 17

PMID 33728251

Citations 10

Authors

Troy C Lund

Terence M Doherty

Julie B Eisengart

Rebecca L Freese

Kyle D Rudser

Ellen B Fung

Bradley S Miller

Klane K White

Paul J Orchard

Chester B Whitley

Lynda E Polgreen

Affiliations

Soon will be listed here.

Abstract

Background: Orthopedic disease progresses in mucopolysaccharidosis type I (MPS I), even with approved therapies and remains a major factor in persistent suffering and disability. Novel therapies and accurate predictors of response are needed. The primary objective of this study was to identify surrogate biomarkers of future change in orthopedic disease.

Methods: As part of a 9-year observational study of MPS I, range-of-motion (ROM), height, pelvic radiographs were measured annually. Biomarkers in year 1 were compared to healthy controls. Linear regression tested for associations of change in biomarkers over the first year with change in long-term outcomes.

Results: MPS I participants (N = 19) were age 5 to 16 years and on average 6.9 ± 2.9 years post treatment initiation. Healthy controls (N = 51) were age 9 to 17 years. Plasma IL-1β, TNF-α, osteocalcin, pyridinolines, and deoxypyridinolines were higher in MPS than controls. Within MPS, progression of hip dysplasia was present in 46% to 77%. A 1 pg/mL increase in IL-6 was associated with -22°/year change in ROM (-28 to -15; < .001), a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -0.024 Z-score/year change in height Z-score (-0.043 to -0.005; = .016), and a 20 nmol/mmol creatinine/year increase in urine PYD was associated with a -2.0%/year change in hip dysplasia measured by Reimers migration index (-3.8 to -0.1; = .037).

Conclusions: Inflammatory cytokines are high in MPS I. IL-6 and PYD were associated with progression in joint contracture, short stature, and hip dysplasia over time. Once validated, these biomarkers may prove useful for predicting response to treatment of skeletal disease in MPS I.

Citing Articles

Evaluation of etanercept (a tumor necrosis factor alpha inhibitor) as an effective treatment for joint disease in mucopolysaccharidosis type I. A case report with whole-body magnetic resonance imaging.

Buchinskaya N, Isupova E, Vechkasova A, Malekov D, Ivanov D, Kostik M Front Med (Lausanne). 2024; 10:1252704.

PMID: 38314027 PMC: 10834648. DOI: 10.3389/fmed.2023.1252704.

Trends in Serum Cytokine Expression in Pediatric Skeletal Dysplasia.

OConnell D, Carroll R, Duker A, Schelhaas A, Postell M, Fawcett P JBMR Plus. 2023; 7(12):e10816.

PMID: 38130766 PMC: 10731102. DOI: 10.1002/jbm4.10816.

Hurler Syndrome Glycosaminoglycans Decrease in Cerebrospinal Fluid without Brain-Targeted Therapy.

Lund T, Braunlin E, Polgreen L, Gupta A, Orchard P, Eisengart J Ann Neurol. 2023; 94(6):1182-1186.

PMID: 37679306 PMC: 11318530. DOI: 10.1002/ana.26786.

Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.

Bodaghi A, Fattahi N, Ramazani A Heliyon. 2023; 9(2):e13323.

PMID: 36744065 PMC: 9884646. DOI: 10.1016/j.heliyon.2023.e13323.

Proteomics identifies novel biomarkers of synovial joint disease in a canine model of mucopolysaccharidosis I.

Zhang C, Gawri R, Lau Y, Spruce L, Fazelinia H, Jiang Z Mol Genet Metab. 2023; 138(2):107371.

PMID: 36709534 PMC: 9918716. DOI: 10.1016/j.ymgme.2023.107371.

References

Simonaro C, DAngelo M, He X, Eliyahu E, Shtraizent N, Haskins M . Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2007; 172(1):112-22. PMC: 2189614. DOI: 10.2353/ajpath.2008.070564. View

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

Langereis E, van Vlies N, Church H, Geskus R, Hollak C, Jones S . Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab. 2014; 114(2):129-37. DOI: 10.1016/j.ymgme.2014.10.012. View

Whitley C, Belani K, Chang P, Summers C, Blazar B, Tsai M . Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993; 46(2):209-18. DOI: 10.1002/ajmg.1320460222. View

Parker H, Bigger B . The role of innate immunity in mucopolysaccharide diseases. J Neurochem. 2018; 148(5):639-651. PMC: 6590380. DOI: 10.1111/jnc.14632. View

Polgreen L, Vehe R, Rudser K, Kunin-Batson A, Jarnes Utz J, Dickson P . Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab. 2016; 117(4):427-30. PMC: 4851859. DOI: 10.1016/j.ymgme.2016.01.012. View

Langereis E, den Os M, Breen C, Jones S, Knaven O, Mercer J . Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation. J Bone Joint Surg Am. 2016; 98(5):386-95. DOI: 10.2106/JBJS.O.00601. View

Stevenson D, Rudser K, Kunin-Batson A, Fung E, Viskochil D, Shapiro E . Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med. 2014; 7(2):159-65. PMC: 4420175. DOI: 10.3233/PRM-140285. View

Raymond G, Pasquali M, Polgreen L, Dickson P, Miller W, Orchard P . Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H. Sci Rep. 2016; 6:38305. PMC: 5133554. DOI: 10.1038/srep38305. View

10.

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

11.

Eisengart J, Rudser K, Tolar J, Orchard P, Kivisto T, Ziegler R . Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2012; 162(2):375-80.e1. PMC: 3524404. DOI: 10.1016/j.jpeds.2012.07.052. View

12.

Clarke L, Wraith J, Beck M, Kolodny E, Pastores G, Muenzer J . Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009; 123(1):229-40. DOI: 10.1542/peds.2007-3847. View

13.

Aldenhoven M, Wynn R, Orchard P, OMeara A, Veys P, Fischer A . Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015; 125(13):2164-72. DOI: 10.1182/blood-2014-11-608075. View

14.

Simonaro C . Cartilage and chondrocyte pathology in the mucopolysaccharidoses: The role of glycosaminoglycan-mediated inflammation. J Pediatr Rehabil Med. 2011; 3(2):85-8. DOI: 10.3233/PRM-2010-0120. View

15.

Chahla S, Frohnert B, Thomas W, Kelly A, Nathan B, Polgreen L . Higher daily physical activity is associated with higher osteocalcin levels in adolescents. Prev Med Rep. 2015; 2:568-571. PMC: 4517293. DOI: 10.1016/j.pmedr.2015.06.017. View

16.

Holley R, Ellison S, Fil D, OLeary C, McDermott J, Senthivel N . Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain. 2017; 141(1):99-116. DOI: 10.1093/brain/awx311. View

17.

Pastores G, Arn P, Beck M, Clarke J, Guffon N, Kaplan P . The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007; 91(1):37-47. DOI: 10.1016/j.ymgme.2007.01.011. View

18.

Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N . Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012; 14(5):R230. PMC: 3580542. DOI: 10.1186/ar4072. View

19.

Emery P, Dorner T . Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis. 2011; 70(12):2063-70. DOI: 10.1136/ard.2010.148015. View

20.

Simonaro C, Ge Y, Eliyahu E, He X, Jepsen K, Schuchman E . Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A. 2009; 107(1):222-7. PMC: 2806747. DOI: 10.1073/pnas.0912937107. View